Microenvironment and Immunology p 38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma

  2012cited by this paper
• Characterization of Wnt/β‐catenin signalling in osteoclasts in multiple myeloma

  2010cited by this paper
• Inhibiting Dickkopf‐1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma

  2009cited by this paper
• Estrogen-dependent and C-C chemokine receptor-2–dependent pathways determine osteoclast behavior in osteoporosis

  2009cited by this paper
• Pathogenesis of myeloma bone disease

  2009cited by this paper
• Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.

  2008cited by this paper
• Novel targets for myeloma bone disease.

  2008cited by this paper
• MCP-1 derived from stromal keratocyte induces corneal infiltration of CD4+ T cells in herpetic stromal keratitis.

  2008cited by this paper
• Inhibition of p38α MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment

  2008cited by this paper
• Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.

  2008influential reference
• Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption.

  2007cited by this paper
• Treatment strategies for bone disease

  2007cited by this paper
• Anti-β2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts

  2007cited by this paper
• RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation.

  2007cited by this paper
• Bone-breaking cancer treatment

  2007cited by this paper
• Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells.

  2006cited by this paper
• Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.

  2006cited by this paper
• Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.

  2006cited by this paper
• MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells.

  2006cited by this paper
• Critical roles of Raf/MEK/ERK and PI3K/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells.

  2005cited by this paper
• MCP-1 Is Induced by Receptor Activator of Nuclear Factor-κB Ligand, Promotes Human Osteoclast Fusion, and Rescues Granulocyte Macrophage Colony-stimulating Factor Suppression of Osteoclast Formation*

  2005cited by this paper
• The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

  2003cited by this paper
• Mechanisms of bone resorption in myeloma.

  2003cited by this paper
• Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts.

  2003cited by this paper
• Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu.

  2003cited by this paper
• Role of the Bone Marrow Microenvironment in Multiple Myeloma

  2002cited by this paper
• Treatment strategies for renal bone disease.

  2001cited by this paper
• A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket

  1997cited by this paper

• No citing papers are available for this paper.